ClinicalTrials.gg
CompletedNCT00396253TROPICS 4Updated Jan 12, 2017Results posted

A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters

A Phase 3 interventional study of Tenecteplase in Dysfunctional Hemodialysis Catheters, sponsored by Genentech, Inc.. Completed. Per ClinicalTrials.gov, last updated 2017-01-12.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
223
Allocation
Not applicable
Sex
All
01

Study summary

This was a Phase III, open-label study conducted at 44 centers in the United States, Canada, and Puerto Rico. 223 subjects who required hemodialysis (HD) and had a dysfunctional HD catheter were enrolled in the study.

Read the detailed description

The study consisted of four visits that corresponded to consecutive HD sessions for each patient, as well as one follow-up visit. Patients could receive up to three treatments with open-label tenecteplase during the study: one or two treatments during an initial treatment course, and eligible patients whose catheter became dysfunctional again within 21 days of the first visit received an additional treatment as part of a retreatment (RT) course.

At Visit 1, patients eligible at the beginning of HD had 2 mL (2 mg) of tenecteplase instilled into each of the two lumens of the HD catheter. After a dwell time of 1 hour, study drug was withdrawn and all subjects underwent HD. The duration of the HD session was not fixed by the study protocol, but rather by the site's HD practice, physician orders, and individual patient response during the session. Patients who did not experience treatment success at the end of Visit 1 had 2 mL (2 mg) of tenecteplase instilled into each lumen of their catheter as part of the initial treatment course. The treatment was left to dwell for an extended time, until the second HD session at Visit 2 (up to 72 hours later). Patients who received extended-dwell tenecteplase had the treatment withdrawn from their catheter at the beginning of Visit 2. Patients underwent HD as prescribed or to the extent possible.

Patients who had treatment success at Visit 1 or Visit 2 and had a recurrence of catheter dysfunction within 21 days of Visit 1 and met the re-treatment eligibility criteria had 2 mL (2 mg) of tenecteplase instilled into each lumen, followed by a 1-hour dwell time at re-treatment Visit 1.

02

Conditions studied

  • Dysfunctional Hemodialysis Catheters

Keywords

  • HD
  • TNKase
  • Hemodialysis
  • Catheter clearance
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: for the Study

  • Clinically stable, in the opinion of the investigator
  • Use of a cuffed, tunneled HD catheter
  • HD prescribed at a blood flow rate (BFR) of ≥300 mL/min
  • Baseline BFR (at any time during the first 60 minutes of HD) of \<300 mL/min at an associated pre-pump negative arterial pressure in the range between and including -240 mmHg and -280 mmHg
  • Baseline BFR (at any time during the first 60 minutes of HD) at least 25 mL/min below the prescribed BFR
  • Demonstrated BFR of ≥300 mL/min (using catheter lines in the customary direction) at an arterial pressure in the range of 0 to -280 mmHg in at least one HD session in the 14 days prior to Visit 1
  • Anticipated use of the same catheter for at least four consecutive HD sessions, on the same type and model of HD apparatus
  • Able to have fluids infused at the volume necessary to instill study drug into the HD catheter

Exclusion Criteria: for the Study

  • HD catheter with sustainable BFR of ≥300 mL/min following subject repositioning
  • HD catheter inserted \<2 days prior to screening
  • Evidence of a mechanical, non-thrombotic cause of HD catheter dysfunction (e.g., kink in the catheter or suture constricting the catheter) or dysfunction caused by known fibrin sheath
  • Use of an implantable port
  • HD catheter that is internally coated with any therapeutic agent (e.g., the Decathlon™ Gold catheter)
  • Anticipated use of catheter for any other type of diagnostic or therapeutic procedure (i.e., other than HD) during study drug treatment
  • Previously treated in this study or any tenecteplase catheter clearance trial
  • Use of any drug or therapy (defined as any drug or therapy that is not FDA approved) within 28 days prior to screening
  • Use of a fibrinolytic agent (e.g. alteplase, tenecteplase, reteplase, or urokinase) within 7 days prior to Visit 1
  • Known to be pregnant or breastfeeding at screening or at Visit 1
  • Known bacteremia or known or suspected infection in the HD catheter
  • Known history of any of the following: intracranial hemorrhage (within the previous 3 years), intracranial aneurysm, or arteriovenous malformation
  • Use of heparin (unfractionated or low molecular weight) or other anticoagulants (e.g., for the treatment of heparin-induced thrombocytopenia) within 24 hours prior to Visit 1, except for heparin used only during HD or for prophylaxis (e.g., heparin lock or deep vein thrombosis prophylaxis)
  • Subjects treated with warfarin only: (INR) >3.0 within 7 days prior to Visit 1, or a target INR range that allows for an INR >3.0
  • Initiation of or increase in dose of Plavix® (clopidogrel bisulfate) within 7 days prior to Visit 1
  • ≥12.0 g/dL if on an erythropoiesis-stimulating agent (e.g., darbepoetin or erythropoietin) and the dose of the erythropoiesis-stimulating agent has not been held or reduced per institutional policy
  • At high risk for bleeding events or embolic complications (i.e., recent pulmonary embolus, deep vein thrombosis, endarterectomy, or right-to-left shunt) in the opinion of the investigator, or with known condition for which bleeding constitutes a significant hazard
  • BFR of \<300 mL/min because of symptomatic hypotension
  • Uncontrolled hypertension in the opinion of the investigator
  • Known to tenecteplase or any component of the formulation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    Tenecteplase

    At each treatment, subjects had 2 mL (2 mg) of tenecteplase instilled into each lumen of their HD catheter. Subjects could receive up to three treatments with tenecteplase, the first two as part of the initial treatment course and one additional treatment as part of the retreatment (RT) course. The first treatment, followed by a 1-hour dwell time, was given to all subjects at Visit 1. At the end of hemodialysis at Visit 1, eligible subjects had a second treatment instilled for an extended dwell time until the start of Visit 2 (up to 72 hours).

    Drug: Tenecteplase

Interventions

  • 2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1

    Treatment success is defined as Blood Flow Rate (BFR) ≥ 300 mL/min and an increase of ≥ 25 mL/min from baseline BFR (without reversal of lines), at an associated arterial pressure in the range of 0 to -280 mmHg, 30 (± 10) minutes prior to the end of hemodialysis and at the end of hemodialysis.

    Time frame: Visit 1 (the first hemodialysis session in which treatment was administered). BFR was measured at the beginning of hemodialysis (Baseline measurement) and at 30 minutes prior to the end of hemodialysis and at the end of hemodialysis.

  2. Targeted Adverse Events From the Initial Study Drug Administration Through the Start of Visit 2 or Until Instillation of Extended-Dwell Tenecteplase

    The primary outcome measure was the number of targeted adverse events, occurring from initial study drug administration through the end of Visit 1 (prior to administration of open-label, extended-dwell tenecteplase) or, for subjects who did not receive open-label, extended-dwell tenecteplase, from initial study administration through the start of Visit 2. Targeted adverse events were defined as intracranial hemorrhage, major bleeding and embolic events, thrombosis, Catheter-related blood stream infection (CRBSIs), and catheter-related complications.

    Time frame: From initial study drug administration to the end of Visit 1 (prior to administration of open-label, extended-dwell tenecteplase) or, for patients who did not receive extended-dwell tenecteplase, from initial study administration to the start of Visit 2.

Secondary outcomes

  1. Percentage of Participants Who Maintained Catheter Function at Visits 2 and 3

    For patients with treatment success at Visit 1 or Visit 2, maintenance of catheter function at subsequent visits was defined as a BFR ≥ 300 mL/min and an increase of ≥ 25 mL/min from baseline BFR (without reversal of lines), at an associated target arterial pressure in the range of 0 to -280 mmHg at the beginning of that HD session (within the first 30 minutes).

    Time frame: Maintenance BFR measurements were taken at the beginning of HD at Visit 2 (2nd consecutive HD session, within 72 hours of Visit 1) and Visit 3 (3rd consecutive HD session, within 72 hours of Visit 2).

  2. Percentage of Participants With Urea Reduction Ratio ≥ 65% at Visit 1

    The urea reduction ratio (URR) was calculated from measurements of blood urea nitrogen (BUN) as follows: (Pre-treatment BUN) - (Post-HD BUN) \* 100% / (Pre-treatment BUN) Pre-treatment URR was assessed within 30-60 minutes after the initiation of HD and does not represent a true baseline value.

    Time frame: At Visit 1 (first hemodialysis session in which treatment was administered) samples for blood urea nitrogen measurements were taken at the beginning of HD (prior to treatment administration) and after HD was completed.

  3. Percentage of Participants With Urea Reduction Ratio ≥ 65% at Visit 2

    The urea reduction ratio (URR) at Visit 2 was calculated for those participants who did not receive extended-dwell tenecteplase at Visit 1 from measurements of blood urea nitrogen (BUN) as follows: (Pre-HD BUN) - (Post-HD BUN) \* 100% / (Pre-HD BUN)

    Time frame: At Visit 2 (2nd consecutive HD session, within 72 hours of Visit 1) samples for blood urea nitrogen measurements were taken prior to HD and after HD was completed.

  4. Change in Blood Flow Rate From Baseline to the End of Hemodialysis at Visit 1

    Change in Blood flow rate (BFR) is the BFR at the end of HD for Visit 1 - BFR at Baseline.

    Time frame: Baseline (beginning of HD at Visit 1) to the end of HD at Visit 1.

  5. Percentage of Participants Who Failed Treatment at Visit 1 With Treatment Success at Visit 2

    Patients who failed treatment at Visit 1 and were treated with extended-dwell tenecteplase were analyzed for Treatment Success at Visit 2. Treatment success at Visit 2 was defined as a BFR ≥ 300 mL/min, without line reversal, and increase of ≥ 25 mL/min from baseline BFR, at an associated target arterial pressure in the range of 0 to -280 mmHg, 30 (± 10) minutes prior to the end of HD and at the end of HD.

    Time frame: BFR was measured 30 minutes before the end of HD and at the end of HD at Visit 2 (2nd consecutive HD session, within 72 hours of Visit 1). Baseline BFR was measured at the beginning of HD at Visit 1.

  6. Percentage of Participants Who Failed Treatment at Visit 1 With a Urea Reduction Ratio ≥ 65% at Visits 2 and 3

    Patients who experienced treatment failure at the end of Visit 1 and were eligible for and treated with extended-dwell tenecteplase at Visit 1 were assessed for Urea Reduction Ratio (URR) at Visits 2 and 3. URR was calculated from blood urea nitrogen (BUN) measurements according to the following: (Pre-HD BUN) - (Post-HD BUN) \* 100% / (Pre-HD BUN)

    Time frame: Blood urea nitrogen measurements were taken prior to HD and at the end of HD at Visits 2 (2nd HD session, within 72 hours after visit 1) and 3 (3rd HD session, within 72 hours of Visit 2)

  7. Change in Blood Flow Rate From Baseline to the End of HD at Visit 2

    Change in Blood flow rate (BFR) is the BFR at the end of HD for Visit 2 - BFR at Baseline.

    Time frame: Baseline (beginning of HD at Visit 1) to the end of HD at Visit 2 (2nd consecutive HD session, within 72 hours of Visit 1).

07

Results

Posted Aug 2, 2011

Participant flow

Participant flow — Overall Study
MilestoneTenecteplase
Started223
Completed210
Not completed13
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject7
Withdrew: Death3
Withdrew: Physician decision1
Withdrew: Change in eligibility status1

Outcome measures

PrimaryPercentage of Participants Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1

Treatment success is defined as Blood Flow Rate (BFR) ≥ 300 mL/min and an increase of ≥ 25 mL/min from baseline BFR (without reversal of lines), at an associated arterial pressure in the range of 0 to -280 mmHg, 30 (± 10) minutes prior to the end of hemodialysis and at the end of hemodialysis.

Time frame:
Visit 1 (the first hemodialysis session in which treatment was administered). BFR was measured at the beginning of hemodialysis (Baseline measurement) and at 30 minutes prior to the end of hemodialysis and at the end of hemodialysis.
Reported as:
Number · Percentage of participants
Percentage of Participants Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1
Percentage of participantsTenecteplase
Percentage of Participants Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 134.1
PrimaryTargeted Adverse Events From the Initial Study Drug Administration Through the Start of Visit 2 or Until Instillation of Extended-Dwell Tenecteplase

The primary outcome measure was the number of targeted adverse events, occurring from initial study drug administration through the end of Visit 1 (prior to administration of open-label, extended-dwell tenecteplase) or, for subjects who did not receive open-label, extended-dwell tenecteplase, from initial study administration through the start of Visit 2. Targeted adverse events were defined as intracranial hemorrhage, major bleeding and embolic events, thrombosis, Catheter-related blood stream infection (CRBSIs), and catheter-related complications.

Time frame:
From initial study drug administration to the end of Visit 1 (prior to administration of open-label, extended-dwell tenecteplase) or, for patients who did not receive extended-dwell tenecteplase, from initial study administration to the start of Visit 2.
Reported as:
Number · Events
Targeted Adverse Events From the Initial Study Drug Administration Through the Start of Visit 2 or Until Instillation of Extended-Dwell Tenecteplase
EventsTenecteplase
Intracranial hemorrhage0
Major bleeding0
Embolic event0
Thrombosis1
Catheter-related blood stream infection2
Catheter-related complication0
SecondaryPercentage of Participants Who Maintained Catheter Function at Visits 2 and 3

For patients with treatment success at Visit 1 or Visit 2, maintenance of catheter function at subsequent visits was defined as a BFR ≥ 300 mL/min and an increase of ≥ 25 mL/min from baseline BFR (without reversal of lines), at an associated target arterial pressure in the range of 0 to -280 mmHg at the beginning of that HD session (within the first 30 minutes).

Time frame:
Maintenance BFR measurements were taken at the beginning of HD at Visit 2 (2nd consecutive HD session, within 72 hours of Visit 1) and Visit 3 (3rd consecutive HD session, within 72 hours of Visit 2).
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained Catheter Function at Visits 2 and 3
percentage of participantsTenecteplase
Visit 2 (n=72)69.4 (58.8 to 80.1)
Visit 3 (n=71)62.0 (50.7 to 73.3)
SecondaryPercentage of Participants With Urea Reduction Ratio ≥ 65% at Visit 1

The urea reduction ratio (URR) was calculated from measurements of blood urea nitrogen (BUN) as follows: (Pre-treatment BUN) - (Post-HD BUN) \* 100% / (Pre-treatment BUN) Pre-treatment URR was assessed within 30-60 minutes after the initiation of HD and does not represent a true baseline value.

Time frame:
At Visit 1 (first hemodialysis session in which treatment was administered) samples for blood urea nitrogen measurements were taken at the beginning of HD (prior to treatment administration) and after HD was completed.
Reported as:
Number · percentage of participants
Percentage of Participants With Urea Reduction Ratio ≥ 65% at Visit 1
percentage of participantsTenecteplase
Percentage of Participants With Urea Reduction Ratio ≥ 65% at Visit 123.8 (18.2 to 29.4)
SecondaryPercentage of Participants With Urea Reduction Ratio ≥ 65% at Visit 2

The urea reduction ratio (URR) at Visit 2 was calculated for those participants who did not receive extended-dwell tenecteplase at Visit 1 from measurements of blood urea nitrogen (BUN) as follows: (Pre-HD BUN) - (Post-HD BUN) \* 100% / (Pre-HD BUN)

Time frame:
At Visit 2 (2nd consecutive HD session, within 72 hours of Visit 1) samples for blood urea nitrogen measurements were taken prior to HD and after HD was completed.
Reported as:
Number · percentage of participants
Percentage of Participants With Urea Reduction Ratio ≥ 65% at Visit 2
percentage of participantsTenecteplase
Percentage of Participants With Urea Reduction Ratio ≥ 65% at Visit 234.6 (25.6 to 43.6)
SecondaryChange in Blood Flow Rate From Baseline to the End of Hemodialysis at Visit 1

Change in Blood flow rate (BFR) is the BFR at the end of HD for Visit 1 - BFR at Baseline.

Time frame:
Baseline (beginning of HD at Visit 1) to the end of HD at Visit 1.
Reported as:
Mean · mL/min
Change in Blood Flow Rate From Baseline to the End of Hemodialysis at Visit 1
mL/minTenecteplase
Change in Blood Flow Rate From Baseline to the End of Hemodialysis at Visit 181.9 ± 123.84
SecondaryPercentage of Participants Who Failed Treatment at Visit 1 With Treatment Success at Visit 2

Patients who failed treatment at Visit 1 and were treated with extended-dwell tenecteplase were analyzed for Treatment Success at Visit 2. Treatment success at Visit 2 was defined as a BFR ≥ 300 mL/min, without line reversal, and increase of ≥ 25 mL/min from baseline BFR, at an associated target arterial pressure in the range of 0 to -280 mmHg, 30 (± 10) minutes prior to the end of HD and at the end of HD.

Time frame:
BFR was measured 30 minutes before the end of HD and at the end of HD at Visit 2 (2nd consecutive HD session, within 72 hours of Visit 1). Baseline BFR was measured at the beginning of HD at Visit 1.
Reported as:
Number · percentage of participants
Percentage of Participants Who Failed Treatment at Visit 1 With Treatment Success at Visit 2
percentage of participantsTenecteplase
Percentage of Participants Who Failed Treatment at Visit 1 With Treatment Success at Visit 249.1 (40.0 to 58.2)
SecondaryPercentage of Participants Who Failed Treatment at Visit 1 With a Urea Reduction Ratio ≥ 65% at Visits 2 and 3

Patients who experienced treatment failure at the end of Visit 1 and were eligible for and treated with extended-dwell tenecteplase at Visit 1 were assessed for Urea Reduction Ratio (URR) at Visits 2 and 3. URR was calculated from blood urea nitrogen (BUN) measurements according to the following: (Pre-HD BUN) - (Post-HD BUN) \* 100% / (Pre-HD BUN)

Time frame:
Blood urea nitrogen measurements were taken prior to HD and at the end of HD at Visits 2 (2nd HD session, within 72 hours after visit 1) and 3 (3rd HD session, within 72 hours of Visit 2)
Reported as:
Number · percentage of participants
Percentage of Participants Who Failed Treatment at Visit 1 With a Urea Reduction Ratio ≥ 65% at Visits 2 and 3
percentage of participantsTenecteplase
URR ≥ 65% at Visit 242.2 (33.3 to 51.2)
URR ≥ 65% at Visit 333.6 (25.0 to 42.2)
SecondaryChange in Blood Flow Rate From Baseline to the End of HD at Visit 2

Change in Blood flow rate (BFR) is the BFR at the end of HD for Visit 2 - BFR at Baseline.

Time frame:
Baseline (beginning of HD at Visit 1) to the end of HD at Visit 2 (2nd consecutive HD session, within 72 hours of Visit 1).
Reported as:
Mean · mL/minute
Change in Blood Flow Rate From Baseline to the End of HD at Visit 2
mL/minuteTenecteplase
Change in Blood Flow Rate From Baseline to the End of HD at Visit 2117.1 ± 139.96

Adverse events

Collected over Begins at initiation of study treatment and ends upon completion of the second visit following the last administration of study treatment or at early termination from the study, whichever is earlier.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tenecteplase—9/223 (4%)36/223 (16.1%)
Most frequent serious events
Most frequent serious events
EventTenecteplase
AnaemiaBlood and lymphatic system disorders1/223
PainGeneral disorders1/223
BacteraemiaInfections and infestations1/223
Catheter BacteraemiaInfections and infestations1/223
GangreneInfections and infestations1/223
Infected Skin UlcerInfections and infestations1/223
SepsisInfections and infestations1/223
Staphylococcal BacteraemiaInfections and infestations1/223
Procedural PainInjury, poisoning and procedural complications1/223
HypertensionVascular disorders1/223
Most frequent other events
Showing 10 of 36
Most frequent other events
EventTenecteplase
NauseaGastrointestinal disorders4/223
HeadacheNervous system disorders4/223
HypotensionVascular disorders3/223
Muscle SpasmsMusculoskeletal and connective tissue disorders2/223
PruritusSkin and subcutaneous tissue disorders2/223
HypertensionVascular disorders2/223
Haemodynamic InstabilityVascular disorders2/223
ConstipationGastrointestinal disorders1/223
DiarrhoeaGastrointestinal disorders1/223
DyspepsiaGastrointestinal disorders1/223

Baseline characteristics

Age, Customized
Age, Customized(participants)Tenecteplase
< 17 years1
>= 17 years to < 65 years120
>= 65 years102
Age, Continuous
Age, Continuous(years)Tenecteplase
Mean61.2 ± 16.3
Gender
Gender(Participants)Tenecteplase
Female124
Male99
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 2 years 10 months after primary completion. A results delay was requested in Jun 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2006
First posted
Nov 6, 2006
Start
Nov 2006
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results delay requested
Jun 10, 2009
Results first posted
Aug 2, 2011
Last update
Jan 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00396253
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 6, 2006
Start date
Nov 2006
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Aug 2, 2011
Last update
Jan 12, 2017

Study contacts

Barbara Gillespie, MD, FASN
study director · Quintiles, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion